These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 28758583)

  • 41. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacogenetics and schizophrenia.
    Foster A; Miller DD; Buckley PF
    Psychiatr Clin North Am; 2007 Sep; 30(3):417-35. PubMed ID: 17720030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
    Nakata Y; Kanahara N; Iyo M
    J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopamine D
    Miyauchi M; Neugebauer NM; Meltzer HY
    J Psychopharmacol; 2017 Apr; 31(4):442-452. PubMed ID: 28347261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.
    Roth BL; Hanizavareh SM; Blum AE
    Psychopharmacology (Berl); 2004 Jun; 174(1):17-24. PubMed ID: 15205874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2009 Mar; 12(2):227-41. PubMed ID: 18687163
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.
    Coyle JT; Balu D; Benneyworth M; Basu A; Roseman A
    Dialogues Clin Neurosci; 2010; 12(3):359-82. PubMed ID: 20954431
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains.
    Citrome L
    J Clin Psychiatry; 2014; 75 Suppl 1():21-6. PubMed ID: 24581451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.
    Garay RP; Citrome L; Samalin L; Liu CC; Thomsen MS; Correll CU; Hameg A; Llorca PM
    Expert Opin Pharmacother; 2016; 17(7):921-36. PubMed ID: 26831200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement.
    Huang M; Kwon S; Oyamada Y; Rajagopal L; Miyauchi M; Meltzer HY
    Pharmacol Biochem Behav; 2015 Nov; 138():49-57. PubMed ID: 26383990
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
    Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism.
    Chung YC; Li Z; Dai J; Meltzer HY; Ichikawa J
    Brain Res; 2004 Oct; 1023(1):54-63. PubMed ID: 15364019
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease.
    Friedman JI; Adler DN; Davis KL
    Biol Psychiatry; 1999 Nov; 46(9):1243-52. PubMed ID: 10560029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
    Brown JW; Rueter LE; Zhang M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    Kapur S; Seeman P
    Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.
    Svensson TH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1145-58. PubMed ID: 14642973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.